New Zealand markets closed

TCR2 Therapeutics Inc. (TCRR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.73-0.15 (-2.18%)
At close: 4:00PM EDT
6.65 -0.08 (-1.19%)
After hours: 06:38PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close6.88
Open6.88
Bid6.65 x 1100
Ask6.72 x 800
Day's range6.59 - 6.90
52-week range6.57 - 35.86
Volume698,316
Avg. volume710,906
Market cap257.061M
Beta (5Y monthly)2.38
PE ratio (TTM)N/A
EPS (TTM)-2.34
Earnings date10 Nov 2021 - 15 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est24.89
  • GlobeNewswire

    TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day

    - gavo-cel recommended Phase 2 dose (RP2D) identification before year-end - Anticipated IND filing for TC-510 in 1Q22 - Identification of CD70-targeted lead candidate - Anticipated allogeneic program lead candidate in 2022 - Expansion of platform into autoimmune diseases with TRuC Tregs - TCR2 to host a webcast on Wednesday, October 20 at 8:00a.m. ET CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of

  • GlobeNewswire

    TCR² Therapeutics to Host R&D Day on October 20, 2021

    CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it will host a virtual R&D Day for analysts and investors at 8:00a.m. ET on Wednesday, October 20, 2021. The meeting will feature updates on the Company’s emerging oncology pipeline including enhancements, novel targets and allogeneic TRuCs as well as TRuC Tregs for autoi

  • GlobeNewswire

    TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy

    CAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the e-poster presentation of new preclinical data at the American Association for Cancer Research (AACR) Virtual Special Conference on Tumor Immunology and Immunotherapy, taking place October 5-6, 2021. The e-poster titled “Expression of an IL-15 Receptor Fusion Protein Enhanc